文献速递病毒性肝炎

同伴辅助远程医疗用于吸毒人群丙型肝炎治疗:一项随机对照试验

Peer-Assisted Telemedicine for Hepatitis C in People Who Use Drugs: A Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在美国俄勒冈州7个农村县,将203名有丙型肝炎病毒血症且过去90天有注射吸毒或非处方阿片类使用的吸毒者随机分为同伴辅助远程医疗丙型肝炎治疗组(TeleHCV)和同伴辅助转诊至当地提供者组(增强常规照护,EUC)。TeleHCV组治疗启动率85% vs EUC组12%(RR 6.7,95%CI 4.0-11.3,P<.001),预期治疗完成日期后12周病毒清除率63% vs 16%(RR 4.1,95%CI 2.5-6.5,P<.001)。

要点

  • 同伴辅助远程医疗组治疗启动率85%,增强常规照护组12%(RR 6.7)。
  • 同伴辅助远程医疗组病毒清除率63%,增强常规照护组16%(RR 4.1)。
  • 该模式在农村吸毒人群中大幅提高丙型肝炎治疗启动和病毒清除。

核心结论

  • 同伴辅助远程医疗治疗模式相比增强常规照护大幅提高了丙型肝炎治疗启动率和病毒清除率。
  • 作者认为在其他农村和低资源环境中复制该模式可通过扩大和分散吸毒人群治疗可及性进一步推进世界卫生组织丙型肝炎消除目标。

研究设计与样本

  • 随机对照试验,纳入美国俄勒冈州7个农村县有丙型肝炎病毒血症且过去90天有注射吸毒或非处方阿片类使用的吸毒者203名(TeleHCV组100名,EUC组103名)。
  • 同伴为所有参与者支持筛查和治疗前实验室评估,并为TeleHCV参与者协助远程医疗访视、药物配送和依从性。
  • 采用广义线性模型估计组间丙型肝炎病毒清除(主要结局)以及治疗启动和完成(次要结局)的差异。
  • 临床试验注册号NCT04798521。

主要发现

  • TeleHCV组100名中85名(85%)启动治疗,EUC组103名中13名(12%)启动治疗(RR 6.7,95%CI 4.0-11.3,P<.001)。
  • TeleHCV组100名中63名(63%)在预期治疗完成日期后12周达到病毒清除,EUC组103名中16名(16%)达到病毒清除(RR 4.1,95%CI 2.5-6.5,P<.001)。
  • 203名随机参与者中大多数为男性(62%)、白人(88%)、近期无家可归(70%),过去30天使用甲基苯丙胺(88%)或芬太尼/海洛因(58%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) elimination requires treating people who use drugs (PWUD), yet <10% of PWUD in the United States access HCV treatment; access is especially limited in rural communities. METHODS: We randomized PWUD with HCV viremia and past 90-day injection drug or nonprescribed opioid use in 7 rural Oregon counties to peer-assisted telemedicine HCV treatment (TeleHCV) versus peer-assisted referral to local providers (enhanced usual care [EUC]). Peers supported screening and pretreatment laboratory evaluation for all participants and facilitated telemedicine visits, medication delivery, and adherence for TeleHCV participants. Generalized linear models estimated group differences in HCV viral clearance (primary outcome) and HCV treatment initiation and completion (secondary outcomes). RESULTS: Of the 203 randomized participants (100 TeleHCV, 103 EUC), most were male (62%), White (88%), with recent houselessness (70%), and used methamphetamines (88%) or fentanyl/heroin (58%) in the past 30 days. Eighty-five of 100 TeleHCV participants (85%) initiated treatment versus 13 of 103 (12%) EUC participants (relative risk [RR], 6.7 [95% confidence interval {CI}, 4.0-11.3]; P < .001). Sixty-three of 100 (63%) TeleHCV participants versus 16 of 103 (16%) EUC participants achieved viral clearance 12 weeks after anticipated treatment completion date (RR, 4.1 [95% CI: 2.5-6.5]; P < .001). CONCLUSIONS: The Peer TeleHCV treatment model substantially increased HCV treatment initiation and viral clearance compared to EUC. Replication in other rural and low-resource settings could further World Health Organization HCV elimination goals by expanding and decentralizing treatment access for PWUD. Clinical Trials Registration. NCT04798521.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Seaman A, Cook R, Leichtling G, et al. Peer-Assisted Telemedicine for Hepatitis C in People Who Use Drugs: A Randomized Controlled Trial. Clin Infect Dis. 2025. PMID: 39602441. doi:10.1093/cid/ciae520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。